Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine plus Interferon vs Lamivudine in HBeAg Positive Chronic Hepatitis B
NCT00140725Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2000
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoint: Proportion of patients with HBeAg seroconversion to anti-HBe. Started Apr 2000; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00140725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140725.